CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | organoammonium salt |
|
Accession: | CHEBI:46850
|
browse the term
|
Synonyms: | related_synonym: | organoammonium salts |
|
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases response to substance increases activity |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Tnf |
tumor necrosis factor |
increases activity |
EXP |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
IDA |
4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings |
RGD |
PMID:8075871 |
RGD:2303390 |
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
ISO |
Methylphenazonium Methosulfate results in increased activity of G6PD protein |
CTD |
PMID:1901343 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
increases activity |
ISO |
Methylphenazonium Methosulfate results in increased activity of PGD protein |
CTD |
PMID:1901343 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Ambenonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
affects cleavage |
EXP |
Ambenonium Chloride affects the cleavage of APP protein |
CTD |
PMID:11099780 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AACS mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA1 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ABCA12 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abca6 |
ATP binding cassette subfamily A member 6 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA6 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACOD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529
|
|
G |
Acp6 |
acid phosphatase 6, lysophosphatidic |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACP6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACSL4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Ada |
adenosine deaminase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ADA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADH1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADORA1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ALB mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AMIGO2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AQP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AREG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ARG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ART3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATF4 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
|
|
G |
Atp5mg |
ATP synthase membrane subunit G |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5MG mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
B3galt4 |
Beta-1,3-galactosyltransferase 4 |
affects response to substance |
ISO |
B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BAMBI mRNA |
CTD |
PMID:20146380 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BCL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Btc |
betacellulin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of BTC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of CASP3 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:31982400 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CASP8 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL11 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO |
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31707104 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL20 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL24 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein |
CTD |
PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCN2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCN3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCR4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCR5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd177 |
CD177 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CD300C2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323
|
|
G |
Cdc6 |
cell division cycle 6 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein] Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein |
CTD |
PMID:36725023 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cfap61 |
cilia and flagella associated protein 61 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CFAP61 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:133,354,400...133,633,310
Ensembl chr 3:133,354,197...133,633,320
|
|
G |
Cfd |
complement factor D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CFD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CHI3L1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Cimap1d |
CIMAP1 family member D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CLCF1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cnfn |
cornifelin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein |
CTD |
PMID:25377654 |
|
NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF2 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctps1 |
CTP synthase 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein |
CTD |
PMID:23445166 PMID:30517752 PMID:31158415 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31158415 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions increases expression |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR4 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA Benzalkonium Compounds results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20713136 PMID:30806763 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CYP51 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DDIT3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DHCR24 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases activity increases expression |
ISO |
Benzalkonium Compounds results in decreased activity of DHCR7 protein Benzalkonium Compounds results in increased expression of DHCR7 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of DLK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP10 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EBP mRNA |
CTD |
PMID:26919959 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of EGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EGR1 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELF3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL1 mRNA |
CTD |
PMID:29155129 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Endou |
endonuclease, poly(U)-specific |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ENDOU mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ENO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ETNK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
|
|
G |
Exo1 |
exonuclease 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EXO1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezr |
ezrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein |
CTD |
PMID:29893927 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fam83a |
family with sequence similarity 83, member A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FAM83A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FGR mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FLG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Foxc1 |
forkhead box C1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803
|
|
G |
Foxn1 |
forkhead box N1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:63,251,400...63,273,710
Ensembl chr10:63,251,400...63,273,710
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLC mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLM mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GPX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HBEGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HERPUD1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HIF1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCR mRNA |
CTD |
PMID:26919959 PMID:31199489 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCS2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMOX1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hoxa7 |
homeobox A7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HOXA7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HSD17B7 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HSPA5 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein |
CTD |
PMID:21742781 PMID:30806763 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ID1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IDI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IFNG protein |
CTD |
PMID:30517752 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL13RA2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL15 protein |
CTD |
PMID:30517752 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il17f |
interleukin 17F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL17F mRNA |
CTD |
PMID:23445166 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL18 protein Benzalkonium Compounds results in increased expression of IL18 mRNA |
CTD |
PMID:30517752 PMID:30806763 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases secretion multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein |
CTD |
PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 PMID:31158415 More...
|
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1f10 |
interleukin 1 family member 10 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL23A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL24 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il27 |
interleukin 27 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL27 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il3 |
interleukin 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il31 |
interleukin 31 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL31 protein |
CTD |
PMID:30517752 |
|
NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037
|
|
G |
Il31ra |
interleukin 31 receptor A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL31RA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767
|
|
G |
Il34 |
interleukin 34 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL34 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000
|
|
G |
Il36a |
interleukin 36, alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400
|
|
G |
Il36b |
interleukin 36, beta |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Il36g |
interleukin 36, gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions affects response to substance increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL6 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 PMID:31158415 PMID:31707104 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions increases response to substance |
ISO |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein |
CTD |
PMID:31158415 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL7R mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INHBA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INSIG1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ISL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm7a |
lysine demethylase 7A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KDM7A mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998
|
|
G |
Kdm8 |
lysine demethylase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of KDM8 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLF2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLK8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Krt2 |
keratin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krtap14 |
keratin associated protein 14 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502
|
|
G |
Lce1m |
late cornified envelope 1M |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LCE1M mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,637,495...178,638,697
Ensembl chr 2:178,637,495...178,638,697
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LDHA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LDLR mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LIF protein |
CTD |
PMID:30517752 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
LOC120097198 |
U6 spliceosomal RNA |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of RNU6-643P |
CTD |
PMID:37149095 |
|
NCBI chr15:99,491,045...99,491,148
Ensembl chr15:99,491,045...99,491,148
|
|
G |
LOC120100208 |
small nucleolar RNA SNORA71 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SNORA71D mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:232,131,169...232,131,300
Ensembl chr 1:232,131,169...232,131,300
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LOXL1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LST1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
|
|
G |
Ltb |
lymphotoxin beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15737199 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MESP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases secretion |
ISO |
Benzalkonium Compounds results in increased secretion of MIF protein |
CTD |
PMID:31707104 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504 Ensembl chr 4:12,790,902...12,799,504
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP12 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity |
EXP |
Benzalkonium Compounds results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
ISO EXP |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA Benzalkonium Compounds results in increased activity of MMP9 protein |
CTD |
PMID:21058936 PMID:30171875 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MSMO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MT2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of NR4A2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nrg2 |
neuregulin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:27,616,542...27,798,505
Ensembl chr18:27,619,661...27,798,505
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
affects response to substance |
ISO |
NTRK3 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Ocln |
occludin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of OCLN protein |
CTD |
PMID:29514330 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of OLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Orm1 |
orosomucoid 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ORM1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein] |
CTD |
PMID:31982400 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PBK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PCSK9 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdcd1 |
programmed cell death 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937
|
|
G |
Pfdn6 |
prefoldin subunit 6 |
affects response to substance |
ISO |
PFDN6 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433
|
|
G |
Pglyrp3 |
peptidoglycan recognition protein 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,479,693...177,490,769
Ensembl chr 2:177,477,407...177,490,736 Ensembl chr 2:177,477,407...177,490,736
|
|
G |
Pgp |
phosphoglycolate phosphatase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGP mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plcxd3 |
phosphatidylinositol-specific phospholipase C, X domain containing 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PLCXD3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384
|
|
G |
Plk2 |
polo-like kinase 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLK2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Polr1d |
RNA polymerase I and III subunit D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of POLR1D mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:7,970,592...8,004,157
Ensembl chr12:7,970,595...8,005,624
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PPARA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAG2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Prokr2 |
prokineticin receptor 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PTGS2 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Ralgdsl2 |
ral guanine nucleotide dissociation stimulator like 2 |
affects response to substance |
ISO |
RGL2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,948,495...4,956,774
Ensembl chr20:4,948,497...4,969,911
|
|
G |
Reg1a |
regenerating family member 1 alpha |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rps18 |
ribosomal protein S18 |
affects response to substance |
ISO |
RPS18 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr20:4,931,768...4,938,315
|
|
G |
RT1-DOa |
RT1 class II, locus DOa |
affects response to substance |
ISO |
HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577
|
|
G |
RT1-DOb |
RT1 class II, locus DOb |
affects response to substance |
ISO |
HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
affects response to substance |
ISO |
HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
|
|
G |
RT1-Hb-ps1 |
RT1 class II, locus Hb, pseudogene 1 |
affects response to substance |
ISO |
HLA-DPB1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression decreases expression |
ISO |
Benzalkonium Compounds results in increased expression of SCD mRNA Benzalkonium Compounds results in decreased expression of SCD1 mRNA |
CTD |
PMID:29155129 PMID:31199489 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpinb13 |
serpin family B member 13 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:23,118,582...23,150,352
Ensembl chr13:23,118,584...23,150,760
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SERPINE1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SESN2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SFN mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfrp4 |
secreted frizzled-related protein 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SFRP4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC16A1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC7A11 mRNA |
CTD |
PMID:30806763 PMID:37149095 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Snora38 |
small nucleolar RNA, H/ACA box 38 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SNORA38 |
CTD |
PMID:37149095 |
|
NCBI chr20:3,660,900...3,661,033
Ensembl chr20:3,660,900...3,661,033 Ensembl chr 9:3,660,900...3,661,033
|
|
G |
Sox21 |
SRY-box transcription factor 21 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:95,292,429...95,296,024
Ensembl chr15:95,292,265...95,296,091
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
G |
Sprr1b |
small proline-rich protein 1B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Sprr2a |
small proline rich protein 2A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2H mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236
|
|
G |
Sprr2b |
small proline rich protein 2B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096
|
|
G |
Sprr2f |
small proline rich protein 2F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2F mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SQLE mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SREBF2 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srms |
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:168,318,511...168,324,915
Ensembl chr 3:168,318,512...168,324,915
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517
|
|
G |
Tapbp |
TAP binding protein |
affects response to substance |
ISO |
TAPBP SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181
|
|
G |
Tfap2b |
transcription factor AP-2 beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGFB1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm3 |
transglutaminase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGM3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075
|
|
G |
Tgm7 |
transglutaminase 7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TGM7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of THBS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of TLR4 protein |
CTD |
PMID:29514330 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmprss11b |
transmembrane serine protease 11B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:21,383,936...21,407,283
Ensembl chr14:21,383,862...21,408,817
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion increases expression |
ISO |
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein |
CTD |
PMID:29953848 PMID:30171875 PMID:30517752 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf13c |
TNF receptor superfamily member 13C |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TP53 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TPI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trem2 |
triggering receptor expressed on myeloid cells 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TREM2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TRIB3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Ulbp1 |
UL16 binding protein 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ULBP1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:1,694,255...1,716,160
|
|
G |
Upk3b |
uroplakin 3B |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UPK3B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:20,630,231...20,637,634
Ensembl chr12:20,631,525...20,637,724
|
|
G |
Uqcrq |
ubiquinol-cytochrome c reductase, complex III subunit VII |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UQCRQ mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of VEGFD mRNA |
CTD |
PMID:20146380 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vtcn1 |
V-set domain containing T cell activation inhibitor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658
|
|
G |
Wdr46 |
WD repeat domain 46 |
affects response to substance |
ISO |
WDR46 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form |
CTD |
PMID:28236482 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XCL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329
|
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression |
ISO |
Benzethonium results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
decreases expression |
ISO |
Benzethonium results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Benzethonium results in increased expression of ASNS mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Benzethonium results in increased expression of CHAC1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Benzethonium results in increased expression of DDIT3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Benzethonium results in increased expression of DDIT4 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
Benzethonium results in increased expression of HERPUD1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ighg1 |
immunoglobulin heavy constant gamma 1 |
decreases expression |
ISO |
Benzethonium results in decreased expression of IGHG1 mRNA |
CTD |
PMID:37149095 |
|
Ensembl chr 6:132,389,370...132,393,397
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
Benzethonium results in increased expression of INSIG1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
decreases activity multiple interactions |
ISO |
Benzethonium results in decreased activity of KCNA3 protein [Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 PMID:23313619 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Benzethonium results in increased expression of LDLR mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
LOC120102574 |
U6 spliceosomal RNA |
increases expression |
ISO |
Benzethonium results in increased expression of RNU6-1014P |
CTD |
PMID:37149095 |
|
NCBI chr 4:102,735,624...102,735,728
Ensembl chr 4:102,735,624...102,735,728
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
Benzethonium results in increased expression of NR4A2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
Benzethonium results in increased expression of PSAT1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Rnu6-767 |
RNA, U6 small nuclear 767 |
decreases expression |
ISO |
Benzethonium results in decreased expression of RNU6-767P |
CTD |
PMID:37149095 |
|
NCBI chr 2:102,241,494...102,241,597
Ensembl chr 2:102,241,494...102,241,597
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Benzethonium results in increased expression of SESN2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Benzethonium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Benzethonium results in increased expression of SLC7A11 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Benzethonium results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Bretylium Tosylate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:16098483 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
ISO |
SLC22A8 protein results in increased uptake of cefoselis cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16098483 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
|
G |
1700009N14Rikl |
RIKEN cDNA 1700009N14 gene like |
increases expression |
EXP |
Chlormequat results in increased expression of 1700009N14RIKL protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:54,456,005...54,457,381
Ensembl chr 5:54,455,893...54,457,677
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ABCD1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of ADARB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
EXP |
Chlormequat results in increased expression of AGTRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Alg12 |
ALG12, alpha-1,6-mannosyltransferase |
decreases expression |
EXP |
Chlormequat results in decreased expression of ALG12 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458
|
|
G |
Alg14 |
ALG14, UDP-N-acetylglucosaminyltransferase subunit |
decreases expression |
EXP |
Chlormequat results in decreased expression of ALG14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:209,368,285...209,445,425
Ensembl chr 2:209,368,312...209,445,431
|
|
G |
Apol9a |
apolipoprotein L9a |
increases expression |
EXP |
Chlormequat results in increased expression of APOL9A protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
increases expression |
EXP |
Chlormequat results in increased expression of ARHGAP20 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739
|
|
G |
Atl1 |
atlastin GTPase 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ATL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
|
|
G |
Atp10b |
ATPase phospholipid transporting 10B |
increases expression |
EXP |
Chlormequat results in increased expression of ATP10B protein |
CTD |
PMID:34958886 |
|
NCBI chr10:27,495,207...27,751,313
Ensembl chr10:27,408,747...27,749,637
|
|
G |
B9d2 |
B9 domain containing 2 |
increases expression |
EXP |
Chlormequat results in increased expression of B9D2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:81,189,395...81,195,383
Ensembl chr 1:81,189,405...81,195,356
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
increases expression |
EXP |
Chlormequat results in increased expression of BET1L protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of BGLAP protein |
CTD |
PMID:28214531 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
C1qc |
complement C1q C chain |
increases expression |
EXP |
Chlormequat results in increased expression of C1QC protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of CAAP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
|
|
G |
Cbx1 |
chromobox 1 |
increases expression |
EXP |
Chlormequat results in increased expression of CBX1 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
increases expression |
EXP |
Chlormequat results in increased expression of CCDC32 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975
|
|
G |
Ccnyl1 |
cyclin Y-like 1 |
increases expression |
EXP |
Chlormequat results in increased expression of CCNYL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:66,071,721...66,121,742
Ensembl chr 9:66,071,543...66,107,999
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
EXP |
Chlormequat results in increased expression of CCS protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
decreases expression |
EXP |
Chlormequat results in decreased expression of CD151 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
EXP |
Chlormequat results in increased expression of CD55 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cfap298 |
cilia and flagella associated protein 298 |
increases expression |
EXP |
Chlormequat results in increased expression of CFAP298 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:30,181,916...30,191,302
Ensembl chr11:30,181,905...30,191,346
|
|
G |
Chmp7 |
charged multivesicular body protein 7 |
increases expression |
EXP |
Chlormequat results in increased expression of CHMP7 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:44,790,983...44,806,216
Ensembl chr15:44,790,996...44,806,216
|
|
G |
Coprs |
coordinator of PRMT5 and differentiation stimulator |
increases expression |
EXP |
Chlormequat results in increased expression of COPRS protein |
CTD |
PMID:34958886 |
|
NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375
|
|
G |
Coq4 |
coenzyme Q4 |
increases expression |
EXP |
Chlormequat results in increased expression of COQ4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
EXP |
Chlormequat results in increased phosphorylation of CREB1 protein |
CTD |
PMID:38552810 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
increases expression |
EXP |
Chlormequat results in increased expression of CSNK1A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
|
|
G |
Ctss |
cathepsin S |
decreases expression |
EXP |
Chlormequat results in decreased expression of CTSS protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of CYP11A1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dap |
death-associated protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of DAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
EXP |
Chlormequat results in increased expression of DCAF13 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
|
|
G |
Dctn6 |
dynactin subunit 6 |
increases expression |
EXP |
Chlormequat results in increased expression of DCTN6 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:58,077,595...58,096,604
Ensembl chr16:58,077,585...58,096,968
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein] |
CTD |
PMID:34958886 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
increases expression |
EXP |
Chlormequat results in increased expression of DEGS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
increases expression |
EXP |
Chlormequat results in increased expression of DNAJC14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645
|
|
G |
Dnmbp |
dynamin binding protein |
increases expression |
EXP |
Chlormequat results in increased expression of DNMBP protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
increases expression |
EXP |
Chlormequat results in increased expression of DYNLT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
Ears2 |
glutamyl-tRNA synthetase 2, mitochondrial |
increases expression |
EXP |
Chlormequat results in increased expression of EARS2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:176,597,986...176,625,848
Ensembl chr 1:176,597,986...176,625,836
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of EEF1A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ELOVL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Elovl5 |
ELOVL fatty acid elongase 5 |
increases expression |
EXP |
Chlormequat results in increased expression of ELOVL5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284
|
|
G |
Eno3 |
enolase 3 |
decreases expression |
EXP |
Chlormequat results in decreased expression of ENO3 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Evc |
EvC ciliary complex subunit 1 |
increases expression |
EXP |
Chlormequat results in increased expression of EVC protein |
CTD |
PMID:34958886 |
|
NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
EXP |
Chlormequat results in decreased expression of FABP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of FANCD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
EXP |
Chlormequat results in increased expression of FBLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Chlormequat results in decreased expression of FOS protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxk2 |
forkhead box K2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of FOXK2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
increases expression |
EXP |
Chlormequat results in increased expression of GABARAP protein |
CTD |
PMID:34958886 |
|
NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GH1 protein |
CTD |
PMID:31704167 PMID:32622971 PMID:38552810 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
EXP |
Chlormequat results in decreased expression of GHR mRNA |
CTD |
PMID:28214531 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Ghrh |
growth hormone releasing hormone |
increases expression |
EXP |
Chlormequat results in increased expression of GHRH protein |
CTD |
PMID:32622971 PMID:38552810 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
increases expression |
EXP |
Chlormequat results in increased expression of GNAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gng5 |
G protein subunit gamma 5 |
decreases expression |
EXP |
Chlormequat results in decreased expression of GNG5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513 Ensembl chr11:77,292,043...77,292,513
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GNRH1 protein |
CTD |
PMID:29447956 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
Chlormequat results in increased expression of GSTA2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gtf2h5 |
general transcription factor IIH subunit 5 |
increases expression |
EXP |
Chlormequat results in increased expression of GTF2H5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:46,656,804...46,663,512
Ensembl chr 1:46,656,859...46,664,939
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
EXP |
Chlormequat results in increased expression of H1-0 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
EXP |
Chlormequat results in increased expression of H1-5 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160
|
|
G |
Hebp2 |
heme binding protein 2 |
increases expression |
EXP |
Chlormequat results in increased expression of HEBP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777
|
|
G |
Herpud2 |
HERPUD family member 2 |
increases expression |
EXP |
Chlormequat results in increased expression of HERPUD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:23,573,374...23,618,380
Ensembl chr 8:23,573,379...23,617,874
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
increases expression |
EXP |
Chlormequat results in increased expression of HNRNPC protein |
CTD |
PMID:34958886 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of HSD3B1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein] |
CTD |
PMID:34958886 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression increases expression |
EXP |
Chlormequat affects the expression of IGF1 protein Chlormequat results in increased expression of IGF1 protein |
CTD |
PMID:28214531 PMID:31704167 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
EXP |
Chlormequat results in decreased expression of INA protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Isoc2b |
isochorismatase domain containing 2b |
increases expression |
EXP |
Chlormequat results in increased expression of ISOC2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:68,972,960...68,993,760
Ensembl chr 1:68,972,960...68,993,757
|
|
G |
Itgb1bp1 |
integrin subunit beta 1 binding protein 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ITGB1BP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037
|
|
G |
Kazn |
kazrin, periplakin interacting protein |
increases expression |
EXP |
Chlormequat results in increased expression of KAZN protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074
|
|
G |
Klhl26 |
kelch-like family member 26 |
decreases expression |
EXP |
Chlormequat results in decreased expression of KLHL26 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328
|
|
G |
Klhl7 |
kelch-like family member 7 |
decreases expression |
EXP |
Chlormequat results in decreased expression of KLHL7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:11,006,366...11,055,399
Ensembl chr 4:11,006,375...11,055,541
|
|
G |
Ldb1 |
LIM domain binding 1 |
increases expression |
EXP |
Chlormequat results in increased expression of LDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:244,864,168...244,890,007
Ensembl chr 1:244,877,173...244,890,013
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
Chlormequat results in increased expression of LHB protein |
CTD |
PMID:29447956 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lrrc7 |
leucine rich repeat containing 7 |
increases expression |
EXP |
Chlormequat results in increased expression of LRRC7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
increases expression |
EXP |
Chlormequat results in increased expression of MACROH2A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072
|
|
G |
Macroh2a2 |
macroH2A.2 histone |
increases expression |
EXP |
Chlormequat results in increased expression of MACROH2A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr20:29,678,194...29,727,867
Ensembl chr20:29,678,222...29,727,891
|
|
G |
Map4 |
microtubule-associated protein 4 |
decreases expression |
EXP |
Chlormequat results in decreased expression of MAP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362
|
|
G |
Mgat4b |
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B |
increases expression |
EXP |
Chlormequat results in increased expression of MGAT4B protein |
CTD |
PMID:34958886 |
|
NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229
|
|
G |
Mospd3 |
motile sperm domain containing 3 |
decreases expression |
EXP |
Chlormequat results in decreased expression of MOSPD3 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:19,095,203...19,100,303
Ensembl chr12:19,095,242...19,099,477
|
|
G |
Mov10 |
Mov10 RNA helicase |
increases expression |
EXP |
Chlormequat results in increased expression of MOV10 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:192,292,041...192,315,142
Ensembl chr 2:192,293,470...192,315,083
|
|
G |
Mpp2 |
MAGUK p55 scaffold protein 2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of MPP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:87,011,434...87,043,883
Ensembl chr10:87,011,434...87,043,896
|
|
G |
Mpv17l2 |
MPV17 mitochondrial inner membrane protein like 2 |
increases expression |
EXP |
Chlormequat results in increased expression of MPV17L2 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212
|
|
G |
Mrpl51 |
mitochondrial ribosomal protein L51 |
increases expression |
EXP |
Chlormequat results in increased expression of MRPL51 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:157,991,756...157,994,715
Ensembl chr 4:157,992,408...157,995,414
|
|
G |
Mrpl54 |
mitochondrial ribosomal protein L54 |
increases expression |
EXP |
Chlormequat results in increased expression of MRPL54 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:8,452,801...8,455,321
Ensembl chr 7:8,452,716...8,455,321
|
|
G |
Mrps14 |
mitochondrial ribosomal protein S14 |
increases expression |
EXP |
Chlormequat results in increased expression of MRPS14 protein |
CTD |
PMID:34958886 |
|
NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915
|
|
G |
Mtrfr |
mitochondrial translation release factor in rescue |
increases expression |
EXP |
Chlormequat results in increased expression of MTRFR protein |
CTD |
PMID:34958886 |
|
NCBI chr12:32,261,569...32,275,258
Ensembl chr12:32,258,435...32,275,258
|
|
G |
Ncl |
nucleolin |
increases expression |
EXP |
Chlormequat results in increased expression of NCL protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Nhp2 |
NHP2 ribonucleoprotein |
increases expression |
EXP |
Chlormequat results in increased expression of NHP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545
|
|
G |
Nipa1 |
NIPA magnesium transporter 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of NIPA1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:106,834,000...106,875,148
Ensembl chr 1:106,834,000...106,874,790
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
EXP |
Chlormequat results in decreased expression of NPR3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression |
EXP |
Chlormequat results in increased expression of NR3C2 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ORAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405
|
|
G |
Pabpc1 |
poly(A) binding protein, cytoplasmic 1 |
increases expression |
EXP |
Chlormequat results in increased expression of PABPC1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744
|
|
G |
Pabpc4 |
poly(A) binding protein, cytoplasmic 4 |
increases expression |
EXP |
Chlormequat results in increased expression of PABPC4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:135,563,142...135,578,985
Ensembl chr 5:135,563,562...135,578,979
|
|
G |
Pccb |
propionyl-CoA carboxylase subunit beta |
increases expression |
EXP |
Chlormequat results in increased expression of PCCB protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234
|
|
G |
Pex26 |
peroxisomal biogenesis factor 26 |
increases expression |
EXP |
Chlormequat results in increased expression of PEX26 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:154,414,332...154,426,954
Ensembl chr 4:154,414,849...154,426,952
|
|
G |
Pgpep1 |
pyroglutamyl-peptidase I |
increases expression |
EXP |
Chlormequat results in increased expression of PGPEP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:18,770,563...18,782,968
Ensembl chr16:18,771,021...18,783,478
|
|
G |
Phldb1 |
pleckstrin homology-like domain, family B, member 1 |
increases expression |
EXP |
Chlormequat results in increased expression of PHLDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:45,003,543...45,051,541
Ensembl chr 8:45,003,538...45,051,522
|
|
G |
Pias3 |
protein inhibitor of activated STAT, 3 |
decreases expression |
EXP |
Chlormequat results in decreased expression of PIAS3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:184,232,546...184,241,455
Ensembl chr 2:184,232,571...184,241,480
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
increases expression |
EXP |
Chlormequat results in increased expression of PIK3CD protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pitpnm2 |
phosphatidylinositol transfer protein, membrane-associated 2 |
increases expression |
EXP |
Chlormequat results in increased expression of PITPNM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:32,347,455...32,479,103
Ensembl chr12:32,380,805...32,479,102
|
|
G |
Pole4 |
DNA polymerase epsilon 4, accessory subunit |
increases expression |
EXP |
Chlormequat results in increased expression of POLE4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097
|
|
G |
Pou1f1 |
POU class 1 homeobox 1 |
increases expression |
EXP |
Chlormequat results in increased expression of POU1F1 protein |
CTD |
PMID:38552810 |
|
NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801
|
|
G |
Pphln1 |
periphilin 1 |
increases expression |
EXP |
Chlormequat results in increased expression of PPHLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:124,538,594...124,629,985
Ensembl chr 7:124,538,627...124,629,985
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
affects expression |
EXP |
Chlormequat affects the expression of PRKACA protein |
CTD |
PMID:38552810 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkar1b |
protein kinase cAMP-dependent type I regulatory subunit beta |
increases expression |
EXP |
Chlormequat results in increased expression of PRKAR1B protein |
CTD |
PMID:34958886 |
|
NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942
|
|
G |
Psmb7 |
proteasome 20S subunit beta 7 |
increases expression |
EXP |
Chlormequat results in increased expression of PSMB7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
increases expression |
EXP |
Chlormequat results in increased expression of RAB6A protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
|
|
G |
Rad17 |
RAD17 checkpoint clamp loader component |
increases expression |
EXP |
Chlormequat results in increased expression of RAD17 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072
|
|
G |
Rhoq |
ras homolog family member Q |
increases expression |
EXP |
Chlormequat results in increased expression of RHOQ protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:7,613,632...7,652,047
Ensembl chr 1:106,622,141...106,623,699
|
|
G |
Rnf113a1 |
ring finger protein 113A1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of RNF113A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762
|
|
G |
Rnf185 |
ring finger protein 185 |
increases expression multiple interactions |
EXP |
Chlormequat results in increased expression of RNF185 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein] |
CTD |
PMID:34958886 |
|
NCBI chr14:78,292,517...78,329,832
Ensembl chr14:78,292,516...78,329,864
|
|
G |
Rspry1 |
ring finger and SPRY domain containing 1 |
increases expression |
EXP |
Chlormequat results in increased expression of RSPRY1 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:10,352,449...10,403,015
Ensembl chr19:10,353,821...10,401,102
|
|
G |
Rtn1 |
reticulon 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of RTN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
increases expression |
EXP |
Chlormequat results in increased expression of S100A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544
|
|
G |
Samd8 |
sterile alpha motif domain containing 8 |
increases expression |
EXP |
Chlormequat results in increased expression of SAMD8 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:2,512,104...2,562,368
Ensembl chr15:2,512,105...2,515,379 Ensembl chr15:2,512,105...2,515,379
|
|
G |
Sar1a |
secretion associated, Ras related GTPase 1A |
increases expression |
EXP |
Chlormequat results in increased expression of SAR1A protein |
CTD |
PMID:34958886 |
|
NCBI chr20:29,623,529...29,635,935
Ensembl chr20:29,623,553...29,635,935
|
|
G |
Shroom1 |
shroom family member 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of SHROOM1 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:37,621,149...37,631,895
Ensembl chr10:37,621,723...37,631,256
|
|
G |
Ski |
Ski proto-oncogene |
increases expression |
EXP |
Chlormequat results in increased expression of SKI protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733
|
|
G |
Slc48a1 |
solute carrier family 48 member 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of SLC48A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:128,915,136...128,923,929
Ensembl chr 7:128,915,195...128,923,024
|
|
G |
Slit3 |
slit guidance ligand 3 |
increases expression |
EXP |
Chlormequat results in increased expression of SLIT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634
|
|
G |
Slu7 |
SLU7 homolog, splicing factor |
increases expression |
EXP |
Chlormequat results in increased expression of SLU7 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:27,908,325...27,923,784
Ensembl chr10:27,908,396...27,923,349
|
|
G |
Smim26 |
small integral membrane protein 26 |
decreases expression |
EXP |
Chlormequat results in decreased expression of SMIM26 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:131,990,147...131,991,779
Ensembl chr 3:131,990,291...131,992,132
|
|
G |
Spns1 |
SPNS lysolipid transporter 1, lysophospholipid |
increases expression |
EXP |
Chlormequat results in increased expression of SPNS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:180,942,088...180,949,415
Ensembl chr 1:180,942,088...180,949,370
|
|
G |
Sppl2b |
signal peptide peptidase-like 2B |
increases expression |
EXP |
Chlormequat results in increased expression of SPPL2B protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:8,843,918...8,856,642
Ensembl chr 7:8,843,918...8,856,608
|
|
G |
Sst |
somatostatin |
affects expression |
EXP |
Chlormequat affects the expression of SST protein |
CTD |
PMID:38552810 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ST3GAL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236
|
|
G |
St7l |
suppression of tumorigenicity 7-like |
decreases expression |
EXP |
Chlormequat results in decreased expression of ST7L protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:192,364,594...192,434,414
Ensembl chr 2:192,364,594...192,487,190
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of STAR protein |
CTD |
PMID:29447956 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stk26 |
serine/threonine kinase 26 |
increases expression |
EXP |
Chlormequat results in increased expression of STK26 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:130,325,064...130,375,674
Ensembl chr X:130,310,885...130,374,291
|
|
G |
Susd2 |
sushi domain containing 2 |
increases expression |
EXP |
Chlormequat results in increased expression of SUSD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
EXP |
Chlormequat results in increased expression of TAF7 protein |
CTD |
PMID:34958886 |
|
NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
increases expression |
EXP |
Chlormequat results in increased expression of TCAF1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309
|
|
G |
Tceanc |
transcription elongation factor A N-terminal and central domain containing |
decreases expression |
EXP |
Chlormequat results in decreased expression of TCEANC protein |
CTD |
PMID:34958886 |
|
NCBI chr X:27,952,539...27,961,038
Ensembl chr X:27,952,457...27,960,940
|
|
G |
Tent2 |
terminal nucleotidyltransferase 2 |
increases expression |
EXP |
Chlormequat results in increased expression of TENT2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:24,380,135...24,432,099
Ensembl chr 2:24,380,225...24,432,099
|
|
G |
Them4 |
thioesterase superfamily member 4 |
decreases expression |
EXP |
Chlormequat results in decreased expression of THEM4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:181,953,550...181,974,708
Ensembl chr 2:181,953,550...181,974,708
|
|
G |
Thoc6 |
THO complex subunit 6 |
increases expression |
EXP |
Chlormequat results in increased expression of THOC6 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:12,700,051...12,705,411
Ensembl chr10:12,700,051...12,706,925
|
|
G |
Tirap |
TIR domain containing adaptor protein |
increases expression |
EXP |
Chlormequat results in increased expression of TIRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432
|
|
G |
Tkt |
transketolase |
increases expression |
EXP |
Chlormequat results in increased expression of TKT protein |
CTD |
PMID:34958886 |
|
NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
|
|
G |
Tmem106c |
transmembrane protein 106C |
increases expression |
EXP |
Chlormequat results in increased expression of TMEM106C protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130
|
|
G |
Tmem184c |
transmembrane protein 184C |
decreases expression |
EXP |
Chlormequat results in decreased expression of TMEM184C protein |
CTD |
PMID:34958886 |
|
NCBI chr19:30,345,183...30,361,275
Ensembl chr19:30,345,290...30,361,269
|
|
G |
Tmem208 |
transmembrane protein 208 |
increases expression |
EXP |
Chlormequat results in increased expression of TMEM208 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:33,203,587...33,206,287
Ensembl chr19:33,203,587...33,212,183
|
|
G |
Tmem222 |
transmembrane protein 222 |
increases expression |
EXP |
Chlormequat results in increased expression of TMEM222 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:145,465,847...145,477,932
Ensembl chr 5:145,465,847...145,484,491
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
affects expression |
EXP |
Chlormequat affects the expression of TNFSF11 mRNA |
CTD |
PMID:28214531 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
increases expression |
EXP |
Chlormequat results in increased expression of TP53I11 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050
|
|
G |
Tra2a |
transformer 2 alpha |
increases expression |
EXP |
Chlormequat results in increased expression of TRA2A protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712
|
|
G |
Tram2 |
translocation associated membrane protein 2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of TRAM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:23,419,204...23,498,745
Ensembl chr 9:23,424,232...23,498,689
|
|
G |
Ttc12 |
tetratricopeptide repeat domain 12 |
increases expression |
EXP |
Chlormequat results in increased expression of TTC12 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:49,799,916...49,847,940
Ensembl chr 8:49,799,920...49,847,087
|
|
G |
Ube2d1 |
ubiquitin-conjugating enzyme E2D 1 |
increases expression multiple interactions |
EXP |
Chlormequat results in increased expression of UBE2D1 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein] |
CTD |
PMID:34958886 |
|
NCBI chr20:17,309,315...17,343,770
Ensembl chr20:17,309,315...17,342,295
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of UCP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Wdr74 |
WD repeat domain 74 |
increases expression |
EXP |
Chlormequat results in increased expression of WDR74 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:205,631,769...205,636,558
Ensembl chr 1:205,631,824...205,636,563
|
|
G |
Wsb2 |
WD repeat and SOCS box-containing 2 |
decreases expression |
EXP |
Chlormequat results in decreased expression of WSB2 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:39,217,645...39,238,634
Ensembl chr12:39,217,648...39,238,640
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
increases expression |
EXP |
Chlormequat results in increased expression of ZEB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
|
G |
Abca3 |
ATP binding cassette subfamily A member 3 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ABCA3 protein |
CTD |
PMID:32763356 |
|
NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of APAF1 protein |
CTD |
PMID:32763356 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ASNS mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of ATP2B4 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of BMP2 mRNA |
CTD |
PMID:23537712 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of BMP4 mRNA |
CTD |
PMID:23537712 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of BMP7 mRNA |
CTD |
PMID:23537712 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
didecyldimethylammonium results in increased cleavage of CASP3 protein |
CTD |
PMID:32763356 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccbe1 |
collagen and calcium binding EGF domains 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CCBE1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CCDC80 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCL2 protein |
CTD |
PMID:19762220 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
didecyldimethylammonium results in decreased expression of and results in decreased secretion of CCL3 protein didecyldimethylammonium results in increased expression of CCL3 protein |
CTD |
PMID:19762220 PMID:32763356 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCL4 protein |
CTD |
PMID:19762220 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCL5 protein |
CTD |
PMID:19762220 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCR1 mRNA |
CTD |
PMID:19762220 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCR2 mRNA |
CTD |
PMID:19762220 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CCR3 mRNA |
CTD |
PMID:19762220 |
|
NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CCR5 mRNA |
CTD |
PMID:19762220 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd24 |
CD24 molecule |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CD24 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cebpg |
CCAAT/enhancer binding protein gamma |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CEBPG mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
|
|
G |
Cldn1 |
claudin 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CLDN1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CLIC4 protein |
CTD |
PMID:32763356 |
|
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression decreases expression |
ISO |
didecyldimethylammonium results in increased expression of COL1A1 mRNA didecyldimethylammonium results in decreased expression of COL1A1 mRNA |
CTD |
PMID:19762220 PMID:23537712 PMID:32763356 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of COL1A2 mRNA |
CTD |
PMID:19762220 PMID:23537712 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of COL8A1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Cpa4 |
carboxypeptidase A4 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CPA4 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:59,188,284...59,212,255
Ensembl chr 4:59,188,284...59,212,255
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of CREBRF mRNA |
CTD |
PMID:32763356 |
|
NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of CRISPLD2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of DDIT3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
didecyldimethylammonium results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
didecyldimethylammonium results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
didecyldimethylammonium results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of DKK1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of DNAJB9 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of EGFR protein |
CTD |
PMID:32763356 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of ENC1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of EREG mRNA |
CTD |
PMID:32763356 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ERN1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fbl |
fibrillarin |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of FBL protein |
CTD |
PMID:32763356 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fhdc1 |
FH2 domain containing 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of FHDC1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:169,790,917...169,829,580
Ensembl chr 2:169,790,947...169,827,896
|
|
G |
Flnc |
filamin C |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of FLNC mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of GDF15 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of GFRA1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of GJA1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of HERPUD1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of HMOX1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ICAM1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icos |
inducible T-cell co-stimulator |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ICOS protein |
CTD |
PMID:30649503 |
|
NCBI chr 9:62,368,075...62,406,900
Ensembl chr 9:62,383,832...62,405,672
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL10 protein |
CTD |
PMID:32763356 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of IL1A mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL1B protein didecyldimethylammonium results in increased expression of and results in increased secretion of IL1B protein |
CTD |
PMID:32763356 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of IL24 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of IL2RA protein |
CTD |
PMID:30649503 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
didecyldimethylammonium results in increased expression of IL4 protein didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL4 protein |
CTD |
PMID:30649503 PMID:32763356 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
didecyldimethylammonium results in increased expression of IL6 protein didecyldimethylammonium results in increased expression of IL6 mRNA didecyldimethylammonium results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:19762220 PMID:32763356 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of IL7R protein |
CTD |
PMID:30649503 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Inhbb |
inhibin subunit beta B |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of INHBB mRNA |
CTD |
PMID:32763356 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of ITGA2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
didecyldimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
didecyldimethylammonium results in decreased activity of KCNH2 protein [didecyldimethylammonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm7a |
lysine demethylase 7A |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of KDM7A mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of KIT mRNA |
CTD |
PMID:32763356 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of KLHL24 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636
|
|
G |
Klrg1 |
killer cell lectin like receptor G1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of KLRG1 protein |
CTD |
PMID:30649503 |
|
NCBI chr 4:155,455,465...155,467,301
Ensembl chr 4:155,455,495...155,467,424
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of LAMP2 protein |
CTD |
PMID:32763356 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
LOC120096740 |
U6 spliceosomal RNA |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of RNU6-659P mRNA |
CTD |
PMID:32763356 |
|
NCBI chr14:88,336,534...88,336,640
Ensembl chr14:88,336,534...88,336,640
|
|
G |
LOC120099051 |
U6 spliceosomal RNA |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of RNU6-301P mRNA |
CTD |
PMID:32763356 |
|
NCBI chr20:8,850,618...8,850,719
Ensembl chr20:8,850,618...8,850,719
|
|
G |
Lrrc15 |
leucine rich repeat containing 15 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of LRRC15 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr11:70,469,817...70,484,268
Ensembl chr11:70,469,804...70,484,267
|
|
G |
Lurap1l |
leucine rich adaptor protein 1-like |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of LURAP1L mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438
|
|
G |
Magi2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of MAGI2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Matn2 |
matrilin 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of MATN2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Mest |
mesoderm specific transcript |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of MEST mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145
|
|
G |
Mfn1 |
mitofusin 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of MFN1 protein |
CTD |
PMID:32763356 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
didecyldimethylammonium results in increased expression of and results in increased secretion of MMP1 protein didecyldimethylammonium results in increased expression of MMP1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mocos |
molybdenum cofactor sulfurase |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of MOCOS mRNA |
CTD |
PMID:32763356 |
|
NCBI chr18:15,931,659...15,977,415
Ensembl chr18:15,931,654...15,977,187
|
|
G |
Myl9 |
myosin light chain 9 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of MYL9 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Ncr3lg1 |
natural killer cell cytotoxicity receptor 3 ligand 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of NCR3LG1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:96,565,664...96,581,825
Ensembl chr 1:96,574,455...96,580,466
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of NPR3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of NREP mRNA |
CTD |
PMID:32763356 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of OPA1 protein |
CTD |
PMID:32763356 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of PARP1 protein |
CTD |
PMID:32763356 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcdhb8 |
protocadherin beta 8 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of PCDHB5 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr18:29,065,466...29,067,805
Ensembl chr18:29,065,466...29,067,805
|
|
G |
Pde1c |
phosphodiesterase 1C |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of PDE1C mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of PPP1R15A mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prr16 |
proline rich 16 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of PRR16 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr18:44,424,348...44,764,796
Ensembl chr18:44,424,616...44,632,329
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of PSAT1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptx3 |
pentraxin 3 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of PTX3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of RGS4 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SAT1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SERPINB2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SESN2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sftpb |
surfactant protein B |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SFTPB protein |
CTD |
PMID:32763356 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpd |
surfactant protein D |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SFTPD protein |
CTD |
PMID:32763356 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of SKP2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Slc22a15 |
solute carrier family 22, member 15 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SLC22A15 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:189,298,836...189,359,902
Ensembl chr 2:189,298,832...189,358,792
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of SLC38A4 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smox |
spermine oxidase |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SMOX mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:118,731,900...118,765,710 Ensembl chr X:118,731,900...118,765,710
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of SQSTM1 protein |
CTD |
PMID:32763356 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
St6galnac5 |
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of ST6GALNAC5 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 2:241,741,933...241,911,214
Ensembl chr 2:241,742,688...241,911,208
|
|
G |
Stc2 |
stanniocalcin 2 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of STC2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of TAGLN mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO |
didecyldimethylammonium results in increased expression of TGFB1 mRNA SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of TGFB1 mRNA] |
CTD |
PMID:23537712 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of TGFB2 mRNA |
CTD |
PMID:23537712 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of TGFB3 mRNA |
CTD |
PMID:23537712 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Thbs2 |
thrombospondin 2 |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of THBS2 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789
|
|
G |
Tmem14a |
transmembrane protein 14A |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of TMEM14A mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 9:23,640,594...23,652,379
Ensembl chr 9:23,733,039...23,734,463 Ensembl chr 9:23,733,039...23,734,463
|
|
G |
Tmem156 |
transmembrane protein 156 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of TMEM156 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449
|
|
G |
Tmem255a |
transmembrane protein 255A |
decreases expression |
ISO |
didecyldimethylammonium results in decreased expression of TMEM255A mRNA |
CTD |
PMID:32763356 |
|
NCBI chr X:116,970,793...117,035,008
Ensembl chr X:116,970,695...117,035,008
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
didecyldimethylammonium results in increased expression of and results in increased secretion of TNF protein |
CTD |
PMID:32763356 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of TP53 protein modified form |
CTD |
PMID:32763356 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of TRIB3 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Tslp |
thymic stromal lymphopoietin |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of TSLP protein |
CTD |
PMID:30649503 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of VIM protein] |
CTD |
PMID:23537712 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Yae1 |
YAE1 maturation factor of ABCE1 |
increases expression |
ISO |
didecyldimethylammonium results in increased expression of YAE1D1 mRNA |
CTD |
PMID:32763356 |
|
NCBI chr17:47,027,033...47,033,549
Ensembl chr17:47,027,019...47,033,546
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of ACHE protein |
CTD |
PMID:16978018 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Echothiophate Iodide binds to ALB protein |
CTD |
PMID:15525694 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity multiple interactions |
ISO |
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine] |
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of NCEH1 protein |
CTD |
PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression decreases activity |
EXP ISO |
Erythromycin Estolate results in decreased expression of ABCB11 mRNA Erythromycin Estolate results in decreased activity of ABCB11 protein |
CTD |
PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCC3 mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCG5 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCG8 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACLY mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACSL1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of APEX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of ASPM mRNA Erythromycin Estolate results in increased expression of ASPM mRNA |
CTD |
PMID:24412560 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Aurkb |
aurora kinase B |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of AURKB mRNA Erythromycin Estolate results in decreased expression of AURKB mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of BAX mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of BCL2 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of BTG2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CACNA1I mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CALU mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CAR1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CAT mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CCN2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CCNA2 mRNA Erythromycin Estolate results in decreased expression of CCNA2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of CCNB1 mRNA Erythromycin Estolate results in increased expression of CCNB1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of CDCA3 mRNA Erythromycin Estolate results in increased expression of CDCA3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CDK1 mRNA Erythromycin Estolate results in decreased expression of CDK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cenpw |
centromere protein W |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CENPW mRNA Erythromycin Estolate results in decreased expression of CENPW mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CES2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CHD2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CTSL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP3A9 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of DDIT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dut |
deoxyuridine triphosphatase |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of DUT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
|
|
G |
Ect2 |
epithelial cell transforming 2 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of ECT2 mRNA Erythromycin Estolate results in increased expression of ECT2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FABP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FADS1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of FAM111A mRNA Erythromycin Estolate results in decreased expression of FAM111A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FASN mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FMO1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of GADD45A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GCK mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of GPX2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:81,649,180...81,747,244
Ensembl chr 4:81,649,175...81,780,617
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of HMMR mRNA Erythromycin Estolate results in decreased expression of HMMR mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGF2R mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGFBP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGFBP2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of IP6K2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Isy1 |
ISY1 splicing factor homolog |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ISY1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:120,276,535...120,297,227
Ensembl chr 4:120,276,292...120,297,188
|
|
G |
Kif20b |
kinesin family member 20B |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of KIF20B mRNA Erythromycin Estolate results in decreased expression of KIF20B mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif23 |
kinesin family member 23 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of KIF23 mRNA Erythromycin Estolate results in decreased expression of KIF23 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of KIF2C mRNA Erythromycin Estolate results in increased expression of KIF2C mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Krt18 |
keratin 18 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of KRT18 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LGALS3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lipc |
lipase C, hepatic type |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of LPIN1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LPL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of MAOB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mir16 |
microRNA 16 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of MIR16 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:153,245,349...153,245,443
Ensembl chr 2:153,245,349...153,245,443
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of MYC mRNA Erythromycin Estolate results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of NCAPH mRNA Erythromycin Estolate results in increased expression of NCAPH mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Noct |
nocturnin |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of NOCT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of NUSAP1 mRNA Erythromycin Estolate results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Obp3 |
alpha-2u globulin PGCL4 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of OBP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:74,842,316...74,845,858
Ensembl chr 5:74,842,316...74,845,757
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of PCLAF mRNA Erythromycin Estolate results in decreased expression of PCLAF mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PDK4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Per1 |
period circadian regulator 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PER1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pygl |
glycogen phosphorylase L |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PYGL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of RAD51 mRNA Erythromycin Estolate results in decreased expression of RAD51 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of RRM2 mRNA Erythromycin Estolate results in increased expression of RRM2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of S100A8 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Serpina7 |
serpin family A member 7 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SERPINA7 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Sertad3 |
SERTA domain containing 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SERTAD3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:82,763,535...82,767,271
Ensembl chr 1:82,763,149...82,769,001
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of SHCBP1 mRNA Erythromycin Estolate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of SPC25 mRNA Erythromycin Estolate results in decreased expression of SPC25 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Spin2b |
spindlin family member 2B |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SPIN2B mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:17,190,573...17,192,351
Ensembl chr X:17,180,474...17,192,351
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SPINK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of STAT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of STYXL1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SUGT1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of THRSP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tmcc1 |
transmembrane and coiled-coil domain family 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TMCC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:149,069,252...149,239,585
Ensembl chr 4:149,069,260...149,239,620
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TSC22D3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Ttr |
transthyretin |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TTR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ugt2a1 |
UDP glucuronosyltransferase family 2 member A1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of UGT2A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:20,521,018...20,545,934
Ensembl chr14:20,517,951...20,545,531
|
|
G |
Zc3h13 |
zinc finger CCCH type containing 13 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ZC3H13 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:50,607,335...50,671,802
Ensembl chr15:50,607,380...50,671,802
|
|
G |
Zfp354a |
zinc finger protein 354A |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ZFP354A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:35,396,242...35,408,069
Ensembl chr10:35,396,231...35,408,068
|
|
G |
Zfp574 |
zinc finger protein 574 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ZFP574 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:80,667,984...80,678,257
Ensembl chr 1:80,664,259...80,679,427
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19299917 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19299917 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
GGTI-2133 inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19299917 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
GGTI-2133 inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; GGTI-2133 inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein] |
CTD |
PMID:19299917 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
decreases geranoylation |
ISO |
GGTI-2133 results in decreased geranoylation of RAP1A protein |
CTD |
PMID:25578243 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
|
|